Physician profile
Michael Josilevich
NPI 1811088552
$1,302.14
in general payments reported to CMS, 2019-2025
20 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $171 · 2021: $13.37 · 2023: $19.75 · 2024: $37.48 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331.04 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $155.33 | 2019-2025 | Airsupra |
| Amgen INC. | $122.94 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $107.74 | 2019-2025 | Mounjaro, Zepbound |
| Dova Pharmaceuticals | $97.69 | 2019 | |
| Glaxosmithkline, LLC. | $92.52 | 2020 | |
| Pfizer INC. | $73.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.02 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.69 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $43.36 | 2019-2025 | Injectafer |
| Exact Sciences Corporation | $31.75 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $25.08 | 2025 | Korlym |
| Abbott Laboratories | $23.22 | 2025 | Freestyle Libre 3 |
| C2n Diagnostics, LLC | $17.35 | 2025 | Precivityad2 |
| Astellas Pharma US INC | $16.93 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.22 | 2019 | |
| Vifor Pharma, INC. | $16.06 | 2019 | |
| Acadia Pharmaceuticals INC | $14.80 | 2025 | Nuplazid |
| Amarin Pharma, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Josilevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.